AMRX AMNEAL PHARMACEUTICALS INC Earnings Reports 8-K Filing 2024 - Reaffirmation of Guidance Amneal Pharmaceuticals reaffirms guidance for the year ended December 31, 2023, with net revenue estimated at $2.37 billion - $2.42 billion and adjusted EBITDA at $540 million - $550 million.Get access to all SEC 8-K filings of the AMNEAL PHARMACEUTICALS INC